Professional
Added to YB: 2025-02-03
Pitch date: 2025-01-31
ACHV [bullish]
Achieve Life Sciences, Inc.
+42.77%
current return
Author Info
Rogue Funds is a value-oriented hedge fund sharing in-depth analysis. Sign up for the newsletter.
Company Info
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
Market Cap
$149.2M
Pitch Price
$3.25
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.09
P/E
-2.00
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Rogue Funds Portfolio Holding: Achieve Life Sciences, Inc.
ACHV: Smoking cessation drug shows safety in trial, 100-person yearlong trial ending July. NDA 2Q25, PDUFA Q4 25/Q1 26. High chance of Priority Review. Likely buyout or bid up pre-approval. Current price undervalues risk/reward. Expect run-up post 6-month trial, larger if July results strong.
Read full article (1 min)